Anatomic distribution of periprostatic adipose tissue : A mapping study of 100 radical prostatectomy specimens
✍ Scribed by Heng Hong; Michael O. Koch; Richard S. Foster; Richard Bihrle; Thomas A. Gardner; Joanne Fyffe; Thomas M. Ulbright; John N. Eble; Liang Cheng
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 260 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND
Because the prostatic capsule is often indistinct, recognition of extraprostatic extension by carcinoma depends heavily on the identification of carcinoma cells in the periprostatic adipose tissue. However, the distribution of adipose tissue along the prostatic surfaces has not been studied extensively.
METHODS
The authors analyzed the periprostatic adipose tissue in specimens from 100 patients treated with radical retropubic prostatectomy and bilateral pelvic lymphadenectomy for prostatecarcinoma. Each specimen was totally embedded and examined by the whole mount method. The presence or absence of adipose tissue on the anterior, posterior, right, and left surfaces of the prostate was determined and analyzed.
RESULTS
Periprostatic adipose tissue was present on 48% of all prostatic surfaces examined. The distribution of periprostatic adipose tissue varied among the different surfaces of the prostate, with the anterior, posterior, right, and left surfaces showing 44%, 36%, 59%, and 57% adipose tissue, respectively. The amount of periprostatic adipose tissue was similar among specimens from operations performed by different surgeons (P = 0.72). However, nerve‐sparing procedures resulted in less adipose tissue (46%) than non‐nerve‐sparing procedures (54%) (P = 0.01).
CONCLUSIONS
Less than half of the prostatic surfaces examined were covered by adipose tissue. The absence of adipose tissue over large areas of the prostatic surface, especially the posterior surface, makes the evaluation of extraprostatic extension difficult and unreliable. Further refinement of the prostate carcinoma staging system is needed. Cancer 2003;97:1639–43. © 2003 American Cancer Society.
DOI 10.1002/cncr.11231